Skip to content

Clinical trials

Pneumonia trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pneumonia Country / region: Germany Clear all

47 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20032
20042
20063
20072
20081
20094
20101
20122
20134
20142
20163
20174
20191
20202
20212
20224
20245
20253

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed27
Recruiting7
Unknown status6
Terminated4
Active, not recruiting2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Melinta Therapeutics, Inc.3
University of Giessen3
Pfizer2
Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps2
University Hospital Schleswig-Holstein2
University of Göttingen2
University of Ulm2
ARCIM Institute Academic Research in Complementary and Integrative Medicine1
Aptarion Biotech AG1
Australian and New Zealand Intensive Care Research Centre1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pneumonia47
Community-Acquired Pneumonia9
Respiratory Tract Infections8
COVID-197
Lung Diseases7
Pneumonia, Viral5
Sepsis5
Infections4
Pneumonia, Bacterial4
Respiratory Distress Syndrome4

Trials

Showing 51 to 47 of 47. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.